Grünenthal establishes US footprint with acquisition

14 November 2018

Continuing its prolific deal-making, German family-owned drugmaker Grünenthal says it has acquired the USA-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the USA.

Averitas Pharma will be commercializing the pain patch Qutenza (8 % capsaicin) for Grünenthal in the USA. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics (Nasdaq: ACOR). Financial terms of the acquisition were not revealed.

In the USA, Qutenza is currently only approved for the treatment of postherpetic neuralgia (PHN). Averitas Pharma will work towards a broader neuropathic pain label from the US Food and Drug Administration.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK